Insights on the Anti-venom Global Market to 2025 - Featuring Pfizer, CSL Limited and Flynn Pharma Among Others -

·4-min read

The "Anti-venom Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to's offering.

The anti-venom market is expected to register a CAGR of nearly 4.7% during the forecast period.

Companies Mentioned

  • Pfizer Inc.

  • Laboratorios Silanes (Bioclon Institute)

  • CSL Limited


  • Merck & Co.

  • Merck KGaA (Sigma Aldrich)

  • Flynn Pharma (Micropharm)

  • Boehringer Ingelheim

Key Market Trends

Polyvalent Antivenoms Segment is Poised to Register Robust Growth.

Polyvalent antivenoms comprise particular antibodies that are capable of counteracting a number of homologous venoms from various species/genera. Polyvalent antivenoms can save lives of victims of snake envenomation, even when the culprit snake is unknown, most usual case, about 80% of all the time, and when a monovalent antivenom can not be chosen.

  • Polyvalent anti-venoms are beneficial in regions where there is a presence of large number of venomous species and when it is difficult to produce monovalent antivenoms against all of them.

  • Furthermore, it is now possible to formulate polyvalent antivenoms with high potencies analogous to those of the equivalent monovalent antivenoms. With good manufacturing processes, these antivenoms have been shown to cause few and minor adverse reactions.

  • Moreover, polyvalent antivenoms demonstrated a wide range of Para specific neutralization of poisons from different species/genera, even from distant geographic areas. Lastly, it is less expensive and easier to produce and handle. Thus, the market for polyvanent antivenoms segment anticipated to have significant growth.

The United States is Expected to Retain Largest Market Share During the Forecast Period

North America anti-venom market is projected to hold significant share with respect to demand and revenue. According to the Center for Disease Control and Prevention (CDC), it has been estimated that 7,000-8,000 people every year receive venomous bites in the United States.

  • Furthermore, the majority of bites in the United States occur in the south-western part of the country, as the rattlesnake population in the eastern states are much lower.

  • In October 2018, Rare Disease Therapeutics, Inc. (RDT) has launched ANAVIP (Crotalidae Immune F(ab')2 (Equine)) an equine-derived antivenin indicated for the management of adult and pediatric patients with North American rattlesnake envenomation.

  • The United States contributes a major share to the anti-venom market owing to the establishment of snake poison control centres, increase in antivenom products, and rise in clinical trial conducting firms for anti-venom products, and established healthcare facilities in the region.

Key Topics Covered:


1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study




4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Awareness on Antivenoms Available

4.2.2 Technological Advancements

4.3 Market Restraints

4.3.1 Complexities Involved in The Preparation of the Correct Immunogens

4.3.2 Lack of Regulatory Capacity for the Control of Antivenoms in Countries

4.4 Porter's Five Force Analysis

4.4.1 Threat of New Entrants

4.4.2 Bargaining Power of Buyers/Consumers

4.4.3 Bargaining Power of Suppliers

4.4.4 Threat of Substitute Products

4.4.5 Intensity of Competitive Rivalry


5.1 By Species

5.1.1 Snake

5.1.2 Scorpion

5.1.3 Spiders

5.1.4 Other Species

5.2 By Antivenom Type

5.2.1 Polyvalent Antivenoms

5.2.2 Monovalent Antivenom

5.2.3 Others

5.3 Geography

5.3.1 North America United States Canada Mexico

5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe

5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific

5.3.4 Middle-East & Africa GCC South Africa Rest of Middle-East & Africa

5.3.5 South America Brazil Argentina Rest of South America


6.1 Company Profiles

6.1.1 Pfizer Inc.

6.1.2 Laboratorios Silanes (Bioclon Institute)

6.1.3 CSL Limited

6.1.4 BTG PLC

6.1.5 Merck & Co.

6.1.6 Merck KGaA (Sigma Aldrich)

6.1.7 Flynn Pharma (Micropharm)

6.1.8 Boehringer Ingelheim


For more information about this report visit

View source version on

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900